Brian Schwartz - 29 Jan 2024 Form 4 Insider Report for Cyclacel Pharmaceuticals, Inc. (CYCC)

Role: Interim Chief Medical Officer, Director
Signature: /s/ Brian Schwartz
Issuer symbol: CYCC
Transactions as of: 29 Jan 2024
Net transactions value: $0
Form type: 4
Filing time: 31 Jan 2024, 16:56:01 UTC
Previous filing: 03 Jul 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	CYCC	Common Stock	Award	$0	+12,500	+462%	$0.000000	15,205	29 Jan 2024	Direct	F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	CYCC	Stock Option (right to buy)	Award	$0	+12,500		$0.000000	12,500	29 Jan 2024	Common Stock	12,500	$2.28	Direct	F2, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Consists of restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock upon vesting. The RSUs vest in equal monthly installments beginning on February 29, 2024, subject to the Reporting Person's continued service through the applicable vesting date.
F2	These securities were granted to Dr. Schwartz in connection with his appointment as interim Chief Medical Officer of Cyclacel Pharmaceuticals, Inc.
F3	The shares underlying the option vest in equal monthly installments beginning on February 29, 2024, subject to the Reporting Person's continued service through the applicable vesting date.